Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Vaccinations01:51

Vaccinations

Overview
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An observational diagnostic accuracy study comparing the urine dipstick with a consensus-based reference standard for the diagnosis of urinary tract infections in older adults.

BMC geriatrics·2026
Same author

New chapter in rabies vaccine development.

The Lancet. Infectious diseases·2026
Same author

Socioeconomic status and migration background as predictors of complicated lower respiratory tract infections in primary care.

Communications medicine·2026
Same author

Pharmacokinetic drug-drug interactions with flucloxacillin and other isoxazolyl penicillins: A systematic literature review and practical guide.

British journal of clinical pharmacology·2026
Same author

Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination.

The Journal of infection·2026
Same author

Identifying and addressing UTI prevention barriers in primary care: a qualitative study.

BJGP open·2025
Same journal

Chagas Disease: An Opportunistic Infection in AIDS.

Current infectious disease reports·2026
Same journal

Area-based Deprivation Indices and Healthcare-Associated Infections: A Narrative Review of Evidence.

Current infectious disease reports·2025
Same journal

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays.

Current infectious disease reports·2024
Same journal

To Tweet or Not to Tweet-a Review of the Viral Power of Twitter for Infectious Diseases.

Current infectious disease reports·2024
Same journal

Web alert.

Current infectious disease reports·2024
Same journal

Bacterial Vaginosis in Postmenopausal Women.

Current infectious disease reports·2023
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

TNF-α Antagonists and Immunization.

Leo G Visser1

  • 1Infectious Disease Specialist, Department of Infectious Diseases, Leiden University Medical Centre, C5P-41, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands, l.g.visser@lumc.nl.

Current Infectious Disease Reports
|April 2, 2011
PubMed
Summary
This summary is machine-generated.

Tumor necrosis factor (TNF) antagonists can impact vaccine efficacy. While secondary responses are often adequate, primary responses to travel vaccines may be poor, and live attenuated vaccines should be avoided.

More Related Videos

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue (NALT) in Mouse Responses to Vaccines
12:21

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue (NALT) in Mouse Responses to Vaccines

Published on: August 1, 2012

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue (NALT) in Mouse Responses to Vaccines
12:21

Examining the Role of Nasopharyngeal-associated Lymphoreticular Tissue (NALT) in Mouse Responses to Vaccines

Published on: August 1, 2012

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Tumor necrosis factor (TNF) antagonists are effective treatments for autoimmune inflammatory diseases.
  • Two main classes exist: soluble TNF receptors and TNF monoclonal antibodies, with distinct properties.
  • TNF antagonists modulate the immune response to infections and vaccinations.

Purpose of the Study:

  • To evaluate the impact of TNF antagonists on immune responses to various vaccines.
  • To compare the effects of different TNF antagonist classes on vaccine immunogenicity.
  • To provide guidance on vaccination strategies for patients on TNF antagonist therapy.

Main Methods:

  • The abstract does not specify methods, but implies analysis of immune responses to vaccines in patients treated with TNF antagonists.
  • Comparison of primary and secondary immune responses to different vaccine types (pneumococcal polysaccharide, inactivated travel vaccines, live attenuated vaccines).

Main Results:

  • The immune response to pneumococcal polysaccharide vaccines is impaired in patients on methotrexate and TNF antagonists.
  • Secondary immune responses to inactivated and live attenuated vaccines (e.g., yellow fever) are generally adequate, but with lower antibody levels.
  • Primary immune response to inactivated travel vaccines is likely poor.

Conclusions:

  • TNF antagonists significantly affect vaccine immunogenicity.
  • Primary vaccination with live attenuated vaccines in patients receiving TNF antagonists should be avoided.
  • Careful consideration of vaccine type and timing is crucial for immunocompromised patients.